AU475978B2 - Tetrahydroimidazo or hexahydropyrimido-2,1-b-quinasolin-2-ones - Google Patents

Tetrahydroimidazo or hexahydropyrimido-2,1-b-quinasolin-2-ones

Info

Publication number
AU475978B2
AU475978B2 AU51668/73A AU5166873A AU475978B2 AU 475978 B2 AU475978 B2 AU 475978B2 AU 51668/73 A AU51668/73 A AU 51668/73A AU 5166873 A AU5166873 A AU 5166873A AU 475978 B2 AU475978 B2 AU 475978B2
Authority
AU
Australia
Prior art keywords
formula
compound
alkyl
phenyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU51668/73A
Other languages
English (en)
Other versions
AU5166873A (en
Inventor
Richard Anthony Partyka Warren Neil Seuerling Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Co
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of AU5166873A publication Critical patent/AU5166873A/en
Application granted granted Critical
Publication of AU475978B2 publication Critical patent/AU475978B2/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU51668/73A 1972-02-04 1973-02-01 Tetrahydroimidazo or hexahydropyrimido-2,1-b-quinasolin-2-ones Expired AU475978B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22372372A 1972-02-04 1972-02-04
USUS223,723 1972-02-04
US29145072A 1972-09-22 1972-09-22
USUS291,450 1972-09-22

Publications (2)

Publication Number Publication Date
AU5166873A AU5166873A (en) 1974-08-01
AU475978B2 true AU475978B2 (en) 1976-09-09

Family

ID=26918072

Family Applications (1)

Application Number Title Priority Date Filing Date
AU51668/73A Expired AU475978B2 (en) 1972-02-04 1973-02-01 Tetrahydroimidazo or hexahydropyrimido-2,1-b-quinasolin-2-ones

Country Status (9)

Country Link
JP (1) JPS5623994B2 (enExample)
AU (1) AU475978B2 (enExample)
BE (1) BE794964A (enExample)
CA (1) CA1009652A (enExample)
DE (1) DE2305575A1 (enExample)
FR (1) FR2173988B1 (enExample)
GB (1) GB1418822A (enExample)
HK (1) HK15581A (enExample)
YU (2) YU210773A (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE31617E (en) * 1972-02-04 1984-06-26 Bristol-Myers Company Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones
NL7807507A (nl) * 1977-07-25 1979-01-29 Hoffmann La Roche Tricyclische verbindingen.
US4146718A (en) * 1978-04-10 1979-03-27 Bristol-Myers Company Alkyl 5,6-dichloro-3,4-dihydro-2(1h)-iminoquinazoline-3-acetate hydrohalides
CA1131631A (en) * 1979-06-20 1982-09-14 Madhukar S. Chodnekar Quinazoline derivatives and pharmaceutical preparations
ZW16481A1 (en) * 1980-08-15 1982-03-10 Hoffmann La Roche Novel imidazoquinazoline derivatives
JPS6028979A (ja) * 1983-07-14 1985-02-14 Dai Ichi Seiyaku Co Ltd イミダゾキナゾリン類化合物
EP0597956A1 (en) * 1991-07-29 1994-05-25 Warner-Lambert Company Quinazoline derivatives as acetylcholinesterase inhibitors
EP0722936B1 (en) 1994-08-09 2004-05-19 Eisai Co., Ltd. Fused pyridazine compound
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US8304420B2 (en) 2006-11-28 2012-11-06 Shire Llc Substituted quinazolines for reducing platelet count
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
GB0808947D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substituted quinazolines
GB0808968D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substitute quinazolines
ES2627848T3 (es) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
MX357121B (es) 2011-03-01 2018-06-27 Synergy Pharmaceuticals Inc Star Proceso de preparacion de agonistas c de guanilato ciclasa.
EP2958577A2 (en) 2013-02-25 2015-12-30 Synergy Pharmaceuticals Inc. Guanylate cyclase receptor agonists for use in colonic cleansing
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
PL3004138T3 (pl) 2013-06-05 2024-07-29 Bausch Health Ireland Limited Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie
CA2920856C (en) 2013-08-09 2026-03-03 Ardelyx, Inc. Ph modulating compounds for inhibiting gastrointestinal phosphate uptake
JP2022533251A (ja) 2019-05-21 2022-07-21 アルデリックス， インコーポレイテッド 患者において血清リン酸塩を低下させるための組み合わせ
CN117062819B (zh) * 2021-03-23 2026-07-17 北京生命科学研究所 多环化合物及其用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE760013A (fr) * 1969-12-18 1971-06-08 Smith Kline French Lab Imidazo et pyrimido -(2,1-b)quinazolines, leurs procedes de preparationet compositions pharmaceutiques en contenant

Also Published As

Publication number Publication date
JPS5623994B2 (enExample) 1981-06-03
YU210773A (en) 1983-02-28
HK15581A (en) 1981-05-01
FR2173988B1 (enExample) 1976-10-22
BE794964A (fr) 1973-08-02
DE2305575C2 (enExample) 1989-01-12
DE2305575A1 (de) 1973-08-09
JPS4886894A (enExample) 1973-11-15
YU151081A (en) 1983-12-31
AU5166873A (en) 1974-08-01
GB1418822A (en) 1975-12-24
CA1009652A (en) 1977-05-03
FR2173988A1 (enExample) 1973-10-12

Similar Documents

Publication Publication Date Title
AU462348B2 (en) Saf-t-jet
AU467469B2 (en) Trifluoromethylmercaptoacetamindocephalosphorins
AU5439373A (en) Pillow-doll combination
AU5166873A (en) Tetrahydroimidazo or hexahydropyrimido-2,1-b-quinasolin-2-ones
AU454372B2 (en) Childsafe actuator-overcap
AU469305B2 (en) Deipenylyl-alkanoylaminopyridine
CA960666A (en) 1-aminomethyl-2,2-diaryl-cyclo-propanecarboxamides
CA986359A (en) Projectile-case connection
AU470359B2 (en) Sulphamoylphenyl-imidazolidinones
AU468159B2 (en) 5-aroyl-furans
AU466344B2 (en) Cycloalkyllactamimides
AU473488B2 (en) 15a, 16a-methylene-4-pregnene
AU471369B2 (en) Diphenylmethoxyethylamines
AU467008B2 (en) d, d-DIARYLIMIDAZOLE-2-METHANOLS
CA1013742A (en) Azabenzo-1,5-diazepines
AU473297B2 (en) Indolylimidoylheterocyclics
AU468599B2 (en) 15-oxasteroids
AU468236B2 (en) 2-acyl-5-nitrothiazoles
AU467526B2 (en) Pyronorifamycins
AU467450B2 (en) IO, n-ANHYDROERYTHEOMYCINS
AU472554B2 (en) Isothocyanobenzoxazoles
AU477938B2 (en) 1-aminomethyl-2, 2-diarylcyclopropane-carboxamide
AU485483B2 (en) Terminating ribbon-conductors
AU469608B2 (en) Oxainoquinazolinones
AU464772B2 (en) 5-aroyl-2-(tetrazol-2-ylmethyl) -pyrroles